BPG is committed to discovery and dissemination of knowledge
Cited by in CrossRef
For: Okajima M, Takamura M, Taniguchi T. Landiolol, an ultra-short-acting β1-blocker, is useful for managing supraventricular tachyarrhythmias in sepsis. World J Crit Care Med 2015; 4(3): 251-257 [PMID: 26261777 DOI: 10.5492/wjccm.v4.i3.251]
URL: https://www.wjgnet.com/2220-3141/full/v4/i3/251.htm
Number Citing Articles
1
Naoyuki Matsuda, Osamu Nishida, Takumi Taniguchi, Masaki Okajima, Hiroshi Morimatsu, Hiroshi Ogura, Yoshitsugu Yamada, Tetsuji Nagano, Akira Ichikawa, Yasuyuki Kakihana. Impact of patient characteristics on the efficacy and safety of landiolol in patients with sepsis-related tachyarrhythmia: Subanalysis of the J-Land 3S randomised controlled studyEClinicalMedicine 2020; 28: 100571 doi: 10.1016/j.eclinm.2020.100571
2
Clemens Gangl, Konstantin A Krychtiuk, Robert Schoenbauer, Walter S Speidl. Landiolol for refractory tachyarrhythmias in the intensive care unit: case reportsEuropean Heart Journal Supplements 2022; 24(Supplement_D): D43 doi: 10.1093/eurheartjsupp/suac026
3
Rajeev Seecheran, Roshni Narayansingh, Stanley Giddings, Marlon Rampaul, Kurt Furlonge, Kamille Abdool, Neal Bhagwandass, Naveen Anand Seecheran. Atrial Arrhythmias in a Patient Presenting With Coronavirus Disease-2019 (COVID-19) InfectionJournal of Investigative Medicine High Impact Case Reports 2020; 8 doi: 10.1177/2324709620925571
4
Mariana Floria, Alexandru Florinel Oancea, Paula Cristina Morariu, Alexandru Burlacu, Diana Elena Iov, Cristina Petronela Chiriac, Genoveva Livia Baroi, Celina Silvia Stafie, Magdalena Cuciureanu, Viorel Scripcariu, Daniela Maria Tanase. An Overview of the Pharmacokinetics and Pharmacodynamics of Landiolol (an Ultra-Short Acting β1 Selective Antagonist) in Atrial FibrillationPharmaceutics 2024; 16(4): 517 doi: 10.3390/pharmaceutics16040517
5
Fabio Guarracino, Andrea Cortegiani, Massimo Antonelli, Astrid Behr, Giandomenico Biancofiore, Alfredo Del Gaudio, Francesco Forfori, Nicola Galdieri, Giacomo Grasselli, Gianluca Paternoster, Monica Rocco, Stefano Romagnoli, Salvatore Sardo, Sascha Treskatsch, Vincenzo Francesco Tripodi, Luigi Tritapepe. The role of beta-blocker drugs in critically ill patients: a SIAARTI expert consensus statementJournal of Anesthesia, Analgesia and Critical Care 2023; 3(1) doi: 10.1186/s44158-023-00126-2
6
Felix Eibensteiner, Emmilie Mosor, Daniel Tihanyi, Sonja Anders, Andrea Kornfehl, Marco Neymayer, Julia Oppenauer, Christoph Veigl, Valentin Al Jalali, Hans Domanovits, Patrick Sulzgruber, Sebastian Schnaubelt. The Impact of Chronic Oral Beta-Blocker Intake on Intravenous Bolus Landiolol Response in Hospitalized Intensive Care Patients with Sudden-Onset Supraventricular Tachycardia—A Post Hoc Analysis of a Cross-Sectional TrialPharmaceutics 2024; 16(6): 839 doi: 10.3390/pharmaceutics16060839
7
Shiavax J. Rao, Arjun Kanwal, Amreen Kanwal, Alexandrina Danilov, William H. Frishman. Landiolol: An Ultra-Short-Acting β-BlockerCardiology in Review 2024; 32(5): 468 doi: 10.1097/CRD.0000000000000555
8
Brian W. Johnston, Chung S. Chean, Rui Duarte, Ruaraidh Hill, Bronagh Blackwood, Danny F. McAuley, Ingeborg D. Welters. Management of new onset atrial fibrillation in critically unwell adult patients: a systematic review and narrative synthesisBritish Journal of Anaesthesia 2022; 128(5): 759 doi: 10.1016/j.bja.2021.11.016
9
Gheorghe-Andrei Dan, Anca R Dan, Andreea Ivanescu, Adrian C Buzea. Acute rate control in atrial fibrillation: an urgent need for the clinicianEuropean Heart Journal Supplements 2022; 24(Supplement_D): D3 doi: 10.1093/eurheartjsupp/suac022
10
Madeleine Perrett, Nisha Gohil, Otilia Tica, Karina V. Bunting, Dipak Kotecha. Efficacy and safety of intravenous beta-blockers in acute atrial fibrillation and flutter is dependent on beta-1 selectivity: a systematic review and meta-analysis of randomised trialsClinical Research in Cardiology 2024; 113(6): 831 doi: 10.1007/s00392-023-02295-0
11
Sebastian Rehberg, Michael Joannidis, Tony Whitehouse, Andrea Morelli. Landiolol for managing atrial fibrillation in intensive careEuropean Heart Journal Supplements 2018; 20(suppl_A): A15 doi: 10.1093/eurheartj/sux039
12
Bruno Levy, Michel Slama, Ines Lakbar, Julien Maizel, Hiromi Kato, Marc Leone, Motoi Okada. Landiolol for Treatment of New-Onset Atrial Fibrillation in Critical Care: A Systematic ReviewJournal of Clinical Medicine 2024; 13(10): 2951 doi: 10.3390/jcm13102951
13
Péter Radics, Boldizsár Kiss, Enikő Kovács, Dávid Pilecky, Zoltán Ruzsa, Éva Straub, Csaba Fejér, László Gellér, Béla Merkely, Endre Zima. A landiolol alkalmazási lehetőségei a kardiológiai és intenzív terápiás ellátásbanOrvosi Hetilap 2022; 163(2): 53 doi: 10.1556/650.2022.32347
14
Salwa A. Abuiessa, Sahar M. El-Gowilly, Hanan M. El-Gowelli, Mai M. Helmy, Mahmoud M. El-Mas. Short-lived sensitization of cardiovascular outcomes of postpartum endotoxemia in preeclamptic rats: Role of medullary solitary tract neuroinflammationEuropean Journal of Pharmacology 2021; 910: 174494 doi: 10.1016/j.ejphar.2021.174494
15
Yoh Arita, Takatsugu Segawa, Shohei Yamamoto, Shinji Hasegawa. Landiolol is effective for the treatment of tachycardia-induced cardiogenic shock in patients during septic shock therapyBMJ Case Reports 2017; : bcr-2017-222268 doi: 10.1136/bcr-2017-222268
16
Sofia Bezati, Antonios Boultadakis, Ioannis Ventoulis, Eftihia Polyzogopoulou, John T. Parissis. Optimal use of intravenous landiolol in acute cardiac careExpert Review of Cardiovascular Therapy 2023; 21(11): 855 doi: 10.1080/14779072.2023.2277354
17
Yasuyuki Kakihana, Osamu Nishida, Takumi Taniguchi, Masaki Okajima, Hiroshi Morimatsu, Hiroshi Ogura, Yoshitsugu Yamada, Tetsuji Nagano, Eiichiro Morishima, Naoyuki Matsuda. Efficacy and safety of landiolol, an ultra-short-acting β1-selective antagonist, for treatment of sepsis-related tachyarrhythmia (J-Land 3S): a multicentre, open-label, randomised controlled trialThe Lancet Respiratory Medicine 2020; 8(9): 863 doi: 10.1016/S2213-2600(20)30037-0
18
Tomáš Janota. (Do we need another intravenous beta-blocker?)Cor et Vasa 2020; 62(6): 625 doi: 10.33678/cor.2020.112
19
Kengo Ayabe, Tomoyoshi Komiyama, Hiroyuki Takekawa, Honsa Kang, Yasuaki Tsumagari, Miwa Ito, Keiichi Ashikaga, Yoshisato Shibata. Differential Effects of Landiolol in Patients with Atrial Fibrillation and Atrial TachycardiaMedicina 2024; 60(11): 1782 doi: 10.3390/medicina60111782
20
Po Huang, Fusheng Liu, Xiao Hu, Bo Li, Xiaolong Xu, Qingquan Liu. Effect of ultrashort-acting β-blockers on 28-day mortality in patients with sepsis with persistent tachycardia despite initial resuscitation: a meta-analysis of randomized controlled trials and trial sequential analysisFrontiers in Pharmacology 2024; 15 doi: 10.3389/fphar.2024.1380175
21
Bapi Gorain, Sulagna Dutta, Utpal Nandy, Pallav Sengupta, Hira Choudhury. Frontiers in Pharmacology of Neurotransmitters2020; : 107 doi: 10.1007/978-981-15-3556-7_4
22
Thi Thom Tran, Calypso Mathieu, Magali Torres, Béatrice Loriod, Linh Thuy Lê, Catherine Nguyen, Monique Bernard, Marc Leone, Nathalie Lalevée. Effect of landiolol on sex-related transcriptomic changes in the myocardium during sepsisIntensive Care Medicine Experimental 2019; 7(1) doi: 10.1186/s40635-019-0263-0
23
Sebastian Schnaubelt, Felix Eibensteiner, Julia Oppenauer, Daniel Tihanyi, Marco Neymayer, Roman Brock, Andrea Kornfehl, Christoph Veigl, Valentin Al Jalali, Sonja Anders, Barbara Steinlechner, Hans Domanovits, Patrick Sulzgruber. Hemodynamic and Rhythmologic Effects of Push-Dose Landiolol in Critical Care—A Retrospective Cross-Sectional StudyPharmaceuticals 2023; 16(2): 134 doi: 10.3390/ph16020134
24
Michihiro Sakai, Satoshi Jujo, Junjiro Kobayashi, Yoshihiko Ohnishi, Masataka Kamei. Use of low-dose β1-blocker for sinus tachycardia in patients with catecholamine support following cardiovascular surgery: a retrospective studyJournal of Cardiothoracic Surgery 2019; 14(1) doi: 10.1186/s13019-019-0966-z
25
Yujiro Matsuishi, Bryan J Mathis, Nobutake Shimojo, Satoru Kawano, Yoshiaki Inoue. <p>Evaluating the Therapeutic Efficacy and Safety of Landiolol Hydrochloride for Management of Arrhythmia in Critical Settings: Review of the Literature</p>Vascular Health and Risk Management 2020; : 111 doi: 10.2147/VHRM.S210561
26
Yahiya Y. Syed. Landiolol: A Review in TachyarrhythmiasDrugs 2018; 78(3): 377 doi: 10.1007/s40265-018-0883-9
27
Liam Joseph O'Bryan, Oliver C Redfern, Jonathan Bedford, Tatjana Petrinic, J Duncan Young, Peter J Watkinson. Managing new-onset atrial fibrillation in critically ill patients: a systematic narrative reviewBMJ Open 2020; 10(3): e034774 doi: 10.1136/bmjopen-2019-034774
28
Salwa A. Abuiessa, Mai M. Helmy, Hanan M. El-Gowelli, Sahar M. El-Gowilly, Mahmoud M. El-Mas. Dysregulated ACE/Ang II/Ang1-7 signaling provokes cardiovascular and inflammatory sequelae of endotoxemia in weaning preeclamptic ratsEuropean Journal of Pharmacology 2022; 936: 175344 doi: 10.1016/j.ejphar.2022.175344
29
信洋 森, 広介 関根, 照彦 高倉. Renal replacement therapy databased development using landiolol in sepsisIryou kikigaku (The Japanese journal of medical instrumentation) 2022; 92(5): 525 doi: 10.4286/jjmi.92.525
30
Martin Unger, Andrea Morelli, Mervyn Singer, Peter Radermacher, Sebastian Rehberg, Helmut Trimmel, Michael Joannidis, Gottfried Heinz, Vladimír Cerny, Pavel Dostál, Christian Siebers, Fabio Guarracino, Francesca Pratesi, Gianni Biancofiore, Massimo Girardis, Pavla Kadlecova, Olivier Bouvet, Michael Zörer, Barbara Grohmann-Izay, Kurt Krejcy, Christoph Klade, Günther Krumpl. Landiolol in patients with septic shock resident in an intensive care unit (LANDI-SEP): study protocol for a randomized controlled trialTrials 2018; 19(1) doi: 10.1186/s13063-018-3024-6